Medicine guide
Atectura Breezhaler
·
- Prescription status not stated
- Breathing, airways, allergies and cough
- Active substance
- Indacaterol;mometasone
- Made by
- Novartis Europharm Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Novartis Europharm Limited |
|---|---|
| Active substance | Indacaterol;mometasone |
| Used in | Breathing, airways, allergies and cough |
| Classification | R03AK · Breathing, airways, allergies and cough |
| Authorised on | 2020-05-30 |
| Last updated by the regulator | 2025-11-20 |
| EMA product number | EMEA/H/C/005067 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.